Where colorectal cancer treatment is heading
Colorectal cancer · Updated Nov 15, 2026
Colorectal cancer is the third most common cancer in the US, with about 150,000 new cases a year, and it is rising in people under 50. Early cancers are treated with surgery, often with chemotherapy, and for rectal cancer with radiation. Treatment increasingly depends on tumor tests: MSI-high or dMMR tumors respond strongly to immunotherapy, and KRAS G12C, BRAF V600E and HER2 changes each have targeted drugs. Research is aimed at sparing people unneeded treatment using blood tests, and at the large majority of tumors (MSS) where immunotherapy has not worked well.
- 2,185studies open or running
- 169phase 3 trials
- 15,816papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
Immunotherapy for dMMR tumors at every stageHappened 86.3% cancer-free at 3 years
Atezolizumab plus chemo after surgery: 86.3% cancer-free at 3 years vs 76.2%. Dostarlimab alone cleared dMMR rectal cancers without surgery.
86.3%: free of cancer at 3 years, vs 76.2% with FOLFOX alone.
BRAF-targeted first treatmentHappened 30.3 months median survival
Encorafenib, cetuximab and FOLFOX doubled median survival to 30.3 months vs 15.1 in BRAF V600E cancer.
30.3: months median survival, vs 15.1 with standard care.
Exercise and aspirin after surgeryHappened 80.3% cancer-free at 5 years
A 3-year exercise program raised 5-year cancer-free survival to 80.3% vs 73.9%. Aspirin halved recurrence in PI3K-mutated cancers.
80.3%: free of cancer at 5 years with exercise, vs 73.9%.
-
6 months
by May 2027
Adagrasib for KRAS G12CLikely
KRYSTAL-10 (461 people) compares adagrasib plus cetuximab with chemotherapy as second treatment; its main follow-up ended January 2026.
A first immunotherapy combination for MSSPossible 10.9 months median survival
After STELLAR-303 extended survival (10.9 vs 9.4 months), zanzalintinib plus atezolizumab could be submitted for approval.
10.9: months median survival, vs 9.4 with regorafenib.
-
12 months
by Nov 2027
Immunotherapy alone or with chemoPossible 72% without progression at 2 years
The NCI COMMIT trial asks whether adding chemotherapy to atezolizumab helps dMMR metastatic disease; due June 2027.
72%: without progression at 2 years with nivolumab plus ipilimumab, vs 14%.
Preventing new polypsPossible
SWOG PACES tests eflornithine and sulindac to prevent new polyps and cancers after early colon cancer; due September 2027.
-
3 years
by late 2029
Targeted first treatments for KRAS G12C and HER2Possible
CodeBreaK 301 (sotorasib, due September 2028) and MOUNTAINEER-03 (tucatinib, due December 2027) test targeted drugs as first treatment.
Amivantamab against cetuximabPossible 29% tumors shrank (early trial)
J&J's OrigAMI-2 (1,000 people, due December 2028) and OrigAMI-3 (700 people, due December 2027) compare amivantamab with standard EGFR antibodies.
29%: of left-sided tumors shrank in an early trial.
Blood tests to guide chemo after surgeryPossible 87% recurrence-free if ctDNA-negative
CIRCULATE-US (1,912 people, due March 2029) uses ctDNA to decide who needs chemotherapy after colon cancer surgery.
87%: free of recurrence at 3 years if ctDNA-negative, vs 49% if positive.
-
5 years
by late 2031
PD-1/VEGF bispecifics for MSS cancerLong shot
Ivonescimab (due May 2028), pumitamig and Pfizer’s PF-08634404 (both due February 2030) replace bevacizumab in first-line chemotherapy.
Immunotherapy instead of surgeryPossible 92% recurrence-free at 2 years
GSK's AZUR-2 (892 people, due March 2029) tests dostarlimab around surgery for dMMR colon cancer, building on cases where tumors disappeared.
92%: free of recurrence at 2 years.
The research paths
Immunotherapy for dMMR tumors
86.3% cancer-free at 3 yearsDetails and 2 trialsHide
About 1 in 7 early colorectal cancers are dMMR. Immunotherapy is moving before surgery, and sometimes replacing it.
WatchAZUR-2; COMMIT.
Targeted drugs by mutation
30.3 months median survivalDetails and 4 trialsHide
BRAF, KRAS G12C and HER2 drugs, combined with EGFR antibodies or chemo, are moving to first treatment.
WatchCodeBreaK 301; MOUNTAINEER-03; KRYSTAL-10.
- Adagrasib plus cetuximab, KRAS G12C (KRYSTAL-10)Mirati / Bristol Myers Squibb · 461 people · fully enrolled Jan 2026
- Sotorasib plus panitumumab and FOLFIRI, KRAS G12C (CodeBreaK 301)Amgen · 450 people · enrolling Sep 2028
- Calderasib, KRAS G12C, first lineMerck · 477 people · enrolling Mar 2029
- Tucatinib plus trastuzumab and chemo, HER2-positive (MOUNTAINEER-03)Pfizer · 400 people · enrolling Dec 2027
New antibodies for MSS cancer
10.9 months median survivalDetails and 5 trialsHide
PD-1/VEGF bispecific antibodies and EGFR-MET antibodies aim to help the majority of tumors that standard immunotherapy misses.
WatchHARMONi-GI3; OrigAMI-2.
- Ivonescimab vs bevacizumab with FOLFOX (HARMONi-GI3)Summit Therapeutics · 900 people · enrolling May 2028
- Pumitamig plus chemo, first lineBristol Myers Squibb · 990 people · enrolling Feb 2030
- PF-08634404 plus chemo (Symbiotic-GI-03)Pfizer · 800 people · enrolling Feb 2030
- Amivantamab plus chemo, first line (OrigAMI-2)Johnson & Johnson · 1,000 people · enrolling Dec 2028
- Amivantamab plus FOLFIRI, second line (OrigAMI-3)Johnson & Johnson · 700 people · enrolling Dec 2027
Blood tests and life after treatment
80.3% cancer-free at 5 yearsDetails and 2 trialsHide
ctDNA blood tests to tailor chemotherapy, and exercise, aspirin and drugs to prevent recurrence.
WatchCIRCULATE-US; PACES.
Borrowed from other cancers
From EGFR-mutant lung cancer
Amivantamab
Phase 3
An EGFR-MET bispecific antibody approved for lung cancer, now in two phase 3 colorectal trials.
From Lung cancer
Ivonescimab and pumitamig
Phase 3
PD-1 or PD-L1 plus VEGF bispecific antibodies first tested in lung cancer.
From HER2-positive breast cancer
Tucatinib
Phase 3
A HER2 pill approved for breast cancer and, with trastuzumab, for later-line HER2-positive colorectal cancer.
Open to join now
-
Stage II or III colon cancer after surgery
ctDNA-guided chemotherapy
Locations and eligibility → -
dMMR stage III or T4 colon cancer
Dostarlimab
Locations and eligibility → -
RAS/BRAF wild-type metastatic, first treatment
Amivantamab plus chemotherapy
Locations and eligibility → -
Metastatic, first treatment
Ivonescimab plus FOLFOX
Locations and eligibility → -
KRAS G12C metastatic, first treatment
Sotorasib plus panitumumab
Locations and eligibility →
See every recruiting Colorectal cancer trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Aspirin fails after liver metastasis treatment
ASAC, Lancet Gastroenterology & Hepatology.
Amivantamab shrinks tumors in heavily treated disease
OrigAMI-1, JCO.
Atezolizumab plus FOLFOX cuts recurrence in dMMR stage III colon cancer
ATOMIC, NEJM.
Standard treatment today
- Stage II and III colon cancerSurgery, then 3 to 6 months of chemotherapy (CAPOX or FOLFOX) for stage III and high-risk stage II; atezolizumab added for dMMR stage III.
- Locally advanced rectal cancerTotal neoadjuvant therapy (chemo and radiation before surgery), with watch-and-wait for complete responders; immunotherapy alone for dMMR.
- Metastatic, first treatmentChemotherapy with bevacizumab or (for RAS wild-type, left-sided) an EGFR antibody; immunotherapy for MSI-high; encorafenib combinations for BRAF V600E.
- Metastatic, later treatmentTrifluridine-tipiracil plus bevacizumab, fruquintinib, regorafenib, and targeted drugs for KRAS G12C or HER2.
- Tests to ask aboutMMR/MSI, RAS, BRAF and HER2 testing on every metastatic tumor; germline testing for Lynch syndrome.
How to read this page, and sourcesHow to read this page, and sources
- Colon and rectal cancers share many treatments but differ in surgery and radiation; ask which applies to you.
- Most results depend on tumor tests (MMR/MSI, RAS, BRAF, HER2).
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Colorectal cancer trials recruiting now →